Serum Leads Way With Heat-Stable Rotavirus Vaccine But Competition Unfazed
Executive Summary
Serum Institute has launched a cut-price oral thermostable rotavirus vaccine in India, but competitors like Hilleman Labs, also developing a heat-stable vaccine in the area, aren’t losing much sleep, for now at least. Serum has also introduced a rabies monoclonal antibody.
You may also be interested in...
Hilleman CEO Moving On, Hands Baton To Ex-Takeda Executive
Hilleman CEO Davinder Gill is leaving the global vaccine R&D organization after eight years at the helm and several mileposts. Incoming CEO Raman Rao takes charge from 1 February.
Hilleman’s Shigella Vaccine Moves To Trials In Europe, Africa In ‘Big Step Forward’
India’s Hilleman Laboratories’ pioneering vaccine to treat shigellosis, a form of dysentery that’s a leading killer of young children, is moving into clinical trials in Europe and Africa, but expected launch date has been pushed back in parallel.
US FDA Looks For Advisory Panel's Blessing Of Development Pathway For Monoclonal Antibodies In Rabies PEP
FDA's Division of Antiviral Products proposes a pathway for sponsors to develop monoclonal antibodies designed for rabies post-exposure prophylaxis as an alternative to anti-rabies virus immunoglobulin, but it wants input from an advisory committee before proceeding.